AMGN241213C287500
- 0.15
- -0.15-50.00%
Amgen Newsroom
10 Health Care Stocks Whale Activity In Today's Session
Market Climbs on CPI Inflation and Likelihood of Rate Cuts | Livestock
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer Remains a Buy on Amgen (AMGN)
BofA Restarts Coverage of 11 Large-cap Biopharmas
Amgen Boosts Quarterly Dividend by Nearly 6%
Amgen Raises Qtr Dividend to $2.38 Vs. $2.25 >AMGN
Express News | Amgen Announces 2025 First Quarter Dividend
Unusual Options Activity: AI, MSTR and Others Attract Market Bets, AI V/OI Ratio Reaches 249.3
Market Falls Wednesday, but Googles Chip Impresses | WST
Google's Quantum Chip Might Have Contacted Parallel Universes | Live Stock
Express News | Amgen Shares Down 1.7% After BofA Global Research Reinstates Coverage With Underperform Rating
Demystifying Amgen: Insights From 13 Analyst Reviews
Express News | B of A Securities Reinstates Underperform on Amgen, Announces $256 Price Target
Amgen Analyst Ratings
AMGEN ANNOUNCES 2025 FIRST QUARTER DIVIDEND
Monday Market Falls, Chinese Stocks Climb, Indices Rebalance | Live Stock
Amgen Announced Blincyto Added To Chemotherapy Significantly Improves Survival In Newly Diagnosed Pediatric Patients With B-cell Precursor Acute Lymphoblastic Leukemia At ASH; Said Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival...
BLINCYTO (BLINATUMOMAB) ADDED TO CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN NEWLY DIAGNOSED PEDIATRIC PATIENTS WITH B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
Weekly Buzz: Now THOSE are records!!